Company intelligence / Profile preview
Restem Group
Miami, Florida, United Statesrestem.com ↗
- Ownership
- Private
- Employees
- ~8
- Development stage
- Phase 2
01
Overview
Restem’s lead asset, Restem-L, has completed Phase 1 trials showing clinically meaningful efficacy and significant reduction in steroid use for idiopathic inflammatory myopathy. The program has received FDA Fast Track and Orphan Drug Designations. A pivotal Phase 2/3 trial (“IIMPACT”) is planned to start soon with interim data expected March 2026. Other pipeline assets are at earlier clinical or preclinical stages.
- Therapeutic areas
- OtherRheumatologyImmunology
- Modalities
- Stem cell therapyMesenchymal stem cell therapyCell therapyProtein (for secretome-based product)Activated natural killer cell therapy (NK cell therapy)
- Industry
- Biotech
02
Drug pipeline
2 assets1 more asset in the full pipeline.
Beyond the preview
Go deeper on Restem Group.
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Clinical trials
Follow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Licensing & deals
Explore licensing agreements, acquisitions, and the assets behind each deal.
- Partners
- Deal terms
- Milestones
Funding history
Trace financing activity and the investors behind a company’s development.
- Funding rounds
- Investors
- Capital raised
Competitive landscape
Compare peer pipelines by target, modality, and therapeutic area.
- Peer companies
- Targets
- Pipeline overlap
Technologies & patents
Explore technology platforms and the patent landscape around relevant assets.
- Platforms
- Patents
- Assignees
Research & analysis
Connect company news and source material to the questions you’re investigating.
- Company news
- Sources
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Restem Group.